Comparative Pharmacology
Head-to-head clinical analysis: EQUANIL versus ETHCHLORVYNOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUANIL versus ETHCHLORVYNOL.
EQUANIL vs ETHCHLORVYNOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-aminobutyric acid (GABA) receptor positive allosteric modulator; increases frequency of chloride channel opening, potentiating inhibitory neurotransmission.
Ethchlorvynol is a sedative-hypnotic with central nervous system depressant effects. Its exact mechanism is unknown, but it may potentiate GABA activity or depress neuronal excitability.
400 mg orally 3-4 times daily; maximum 2400 mg/day. Alternatively, 200 mg orally 3-4 times daily for mild anxiety.
500 mg to 1 g orally at bedtime as needed for insomnia.
None Documented
None Documented
Terminal elimination half-life is 6-20 hours (mean 10 hours). In hepatic cirrhosis, half-life may be prolonged to 24-36 hours due to impaired clearance.
Clinical Note
moderateEthchlorvynol + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Fluticasone propionate."
Clinical Note
moderateEthchlorvynol + Clemastine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Clemastine."
Clinical Note
moderateEthchlorvynol + Venlafaxine
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Venlafaxine."
Clinical Note
moderate10-25 minutes (initial rapid distribution phase); terminal elimination half-life approximately 4-6 hours in adults (prolonged in liver disease due to reduced clearance).
Primarily renal excretion of conjugated metabolites (inactive); approximately 90% of a dose is excreted in urine, with less than 10% in feces. Less than 5% is excreted unchanged.
Renal: <1% unchanged; Hepatic metabolism to inactive conjugates; Fecal: minimal. Approximately 90% of a dose is excreted in urine as glucuronide conjugates within 24 hours.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic
Ethchlorvynol + Nefazodone
"The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Nefazodone."